Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 4/20 | 0.61 |
| ▸ | PTPRC | P08575 | 1/20 | 0.48 |
| ▸ | PTPRG | P23470 | 1/20 | 0.48 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.47 |
| ▸ | PDE5A | O76074 | 2/20 | 0.44 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | RXRG | P48443 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27959678 | 0.79 | PTPRG (0.61) | PTGER4PTPRCPTPRGHCAR2CTBP2 | |
| SCHEMBL4304151 | 0.79 | PTGER4 (0.66) | PTGER4PTGER2MAPTMAPK1 | |
| SCHEMBL2351632 | 0.78 | PTGER4 (1.00) | PTGER4PTGER2 | |
| SCHEMBL4096607 | 0.76 | PNMT (0.44) | PTGER4MAPT | |
| SCHEMBL17428963 | 0.74 | PDE5A (0.50) | PTGER4PTPRCPTPRGHCAR2CTBP2 | |
| SCHEMBL5367116 | 0.74 | HCAR2 (0.50) | PTGER4HCAR2CTBP2PTGER2MAPT | |
| SCHEMBL7374000 | 0.74 | TSHR (0.57) | HCAR2CTBP2RXRARXRBRXRG | |
| SCHEMBL4084814 | 0.73 | PTGER4 (0.61) | PTGER4PTPRCPTPRGHCAR2CTBP2 | |
| SCHEMBL14108950 | 0.72 | GPR52 (0.57) | HCAR2PDE5AMAPT | |
| SCHEMBL2493017 | 0.72 | DAO (0.48) | PTGER4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969394-B2 | Thiophenecarboxamide derivatives as EP4 receptor ligands | MERCK FROSST CANADA LTD. (CA) | 2015-03-03 | — | — | US | disclosed |
| US-8969394-B2 | Thiophenecarboxamide derivatives as EP4 receptor ligands | MERCK FROSST CANADA LTD. (CA) | 2015-03-03 | — | — | US | disclosed |
| US-8969394-B2 | Thiophenecarboxamide derivatives as EP4 receptor ligands | MERCK FROSST CANADA LTD. (CA) | 2015-03-03 | — | — | US | disclosed |
| EP-2054401-B1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | MERCK CANADA INC (CA) | 2013-05-01 | — | — | EP | disclosed |
| EP-2054401-B1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | MERCK CANADA INC (CA) | 2013-05-01 | — | — | EP | disclosed |
| US-20090247596-A1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | MERCK CANADA INC. (CA) | 2009-10-01 | — | — | US | disclosed |
| US-20090247596-A1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | MERCK CANADA INC. (CA) | 2009-10-01 | — | — | US | disclosed |
| US-20090247596-A1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | MERCK CANADA INC. (CA) | 2009-10-01 | — | — | US | disclosed |
| EP-2054401-A1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | Merck Frosst Canada Ltd. (CA) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008017164-A1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | MERCK FROSST CANADA LTD. (CA) | 2008-02-14 | — | — | WO | disclosed |
| WO-2008017164-A1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | MERCK FROSST CANADA LTD. (CA) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247596-A1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTPRC 3449/4885PTPRG 2337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.